Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1, Phase 2]
The first-in-human study of SAR443579 in children and adults with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemi…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Clinical trial sponsored by the National Cancer Institute studying individuals and families with DDX41 or similar cancer predisposition vari…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) [Phase 3]
Phase 3 study evaluating MBG453 in combination with azacitidine in adults with intermediate/high/very high risk myelodysplastic syndromes (p…
-
EMA approval · 2025-12-12EMA Authorised: Azacitidine Mylan (azacitidine) — Mylan Pharmaceuticals Limited
EU authorisation granted for Azacitidine Mylan for treatment of myelodysplastic syndromes and certain leukemias, expanding access to azaciti…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS [NA]
A clinical trial evaluating whole genome sequencing (ChromoSeq) as an adjunct to conventional genomic profiling in myelodysplastic syndromes…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy [Phase 2]
Phase 2 trial evaluating the combination of sirolimus and azacitidine in adults with high-risk myelodysplastic syndrome or acute myeloid leu…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms [Phase 2]
Phase 2 study evaluating luspatercept for anemia in patients with lower-risk myelodysplastic syndromes or non-proliferative myeloproliferati…
-
EMA approval · 2025-12-09EMA Authorised: Dacogen (decitabine) — Janssen-Cilag International N.V.
The EMA authorised Dacogen (decitabine) for use in myeloid leukemias, including myelodysplastic syndromes and acute myeloid leukemia.
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
An ongoing clinical trial investigating muscle dysfunction in patients with hematologic diseases referred for stem cell transplantation.
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors [Phase 2]
Phase 2 study evaluating exercise training with nicotinamide riboside (NR) supplementation to improve fitness in adolescent/young adult hema…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan
This completed clinical trial examines real-world treatment patterns and outcomes for patients with myelodysplastic syndromes, focusing on l…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS [Phase 1, Phase 2]
Clinical trial investigating expanded natural killer cells after haploidentical hematopoietic stem cell transplantation for acute myeloid le…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes [Phase 1, Phase 2]
Phase 1/Phase 2 trial of eltanexor with Inqovi in high-risk myelodysplastic syndromes was terminated; results have been posted.
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS [Phase 2]
A Phase 2 clinical trial is investigating a Venetoclax-containing regimen with microtransplant for patients with intermediate-risk or higher…
-
EMA approval · 2025-11-24EMA Authorised: Reblozyl (Luspatercept) — Bristol Myers Squibb Pharma EEIG
The European Medicines Agency authorised Reblozyl (luspatercept) by Bristol Myers Squibb Pharma EEIG for treating anemia associated with bet…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). [Phase 3]
A Phase 3 clinical trial (GLORA-4) is evaluating lisaftoclax (APG-2575) in combination with azacitidine for higher-risk myelodysplastic synd…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor [Phase 2]
Phase 2 clinical trial update evaluating post-transplantation benadamustine and cyclophosphamide in high-risk myeloid malignancies with part…
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials [Phase 3]
This clinical trial update describes a Phase 3 study evaluating the long-term safety of luspatercept in participants who have previously par…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine [Phase 1]
A Phase 1 clinical trial evaluating a haploidentical bone marrow transplant using post-transplant cyclophosphamide and bendamustine has comp…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML [Phase 1]
Phase 1 clinical trial evaluating danvatirsen as monotherapy followed by combination with venetoclax in relapsed/refractory myelodysplastic …
-
CLINICAL_TRIALS withdrawal · 2025-11-10Clinical Trial Update: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies [Phase 1]
A Phase 1 study of Dual-Signaling Protein 107 (DSP107) in hematologic malignancies has been terminated, including studies in Acute Myeloid L…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants [Phase 3]
Clinical trial update for a Phase 3 study of luspatercept in lower-risk myelodysplastic syndrome; the study is currently active but not recr…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating maintenance therapy with the IDH1 inhibitor ivosidenib after allogeneic stem cell transplantation in IDH1-mutant my…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Investigation of the Genetics of Hematologic Diseases
A St. Jude-sponsored clinical trial update indicates a study on the genetics of hematologic diseases is currently recruiting, covering sever…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) [Phase 2]
Phase 2 study update for participants who previously took ASTX727 (oral decitabine/cedazuridine) that is currently enrolling by invitation.